Bausch Health Companies (BHC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Nedelcovych from TD Cowen maintained a Hold rating on the stock and has a $7.00 price target.
Michael Nedelcovych has given his Hold rating due to a combination of factors impacting Bausch Health Companies. The company’s first-quarter financial results fell short of expectations, with total revenue and earnings per share missing the analyst’s estimates. Operating income was also lower than projected, largely due to higher than anticipated SG&A expenses and costs related to Bausch & Lomb’s research and development activities.
Despite a slight increase in the 2025 revenue guidance for consolidated Bausch Health Companies, the EBITDA guidance was revised downward, reflecting concerns about future profitability. Additionally, the potential benefits of separating Bausch & Lomb appear less likely to materialize, contributing to a more cautious outlook. These elements combined have led to a reduced price target and a Hold rating, indicating a neutral stance on the stock’s near-term performance.
According to TipRanks, Nedelcovych is an analyst with an average return of -14.5% and a 38.24% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Royalty Pharma, and Molecular Partners AG.
In another report released yesterday, RBC Capital also reiterated a Hold rating on the stock with a $10.00 price target.